Zevra Therapeutics (ZVRA) Stock
Clinical-stage biotech company advancing treatments through research trials. Here's the price, business snapshot, and what's worth knowing about Zevra Therapeutics in October 2026.
Zevra Therapeutics Inc (ZVRA) is a clinical-stage biotechnology company; its market capitalisation is approximately $623.10M. Investors should know it is a development-led business where value is driven by research milestones, regulatory decisions and partnership activity rather than recurring revenues. That profile means share moves can be sharp around trial readouts, licensing announcements or quarterly cash updates. Typical considerations for prospective investors include the company’s pipeline stage, trial timelines, cash runway and potential for dilution if additional financing is required. As with many small-cap biotech firms, outcomes are binary and uncertainty is high: successful clinical data can create upside, while setbacks may materially reduce value. This summary provides general educational information and is not personalised investment advice; suitability depends on your objectives, time horizon and risk tolerance, so review regulatory filings and consult a professional if unsure.
Zevra Therapeutics (ZVRA) Stock Forecast
Analyst price target, next 12 months
$23.45
+105.9% vs today's $11.39
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Zevra Therapeutics have a consensus 12-month target of $23.45, above the current price of $11.39.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 12 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ZEVRA's stock with a target price of $23.45, indicating strong growth potential.
Financial Health
Zevra Therapeutics is performing well, with strong revenue and excellent profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Catalyst-driven story
Trial readouts and regulatory milestones can move the share price sharply; outcomes are binary and performance can vary.
R&D and innovation
Value is shaped by the success of development programmes and partnerships, though R&D is costly and success is uncertain.
Size and liquidity
With a market cap near $623M, the stock can be more volatile and less liquid; consider diversification and your risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
